

**Policy** # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

## Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers electrical stimulation for the treatment of wounds, including but not limited to low-intensity direct current (LIDC), high-voltage pulsed current (HVPC), alternating current (AC), and transcutaneous electrical nerve stimulation (TENS), to be **investigational.\*** 

Based on review of available data, the Company considers electrical stimulation performed by individuals in the home setting for the treatment of wounds to be **investigational.**\*

Based on review of available data, the Company considers electromagnetic therapy for the treatment of wounds to be **investigational.\*** 

## **Background/Overview**

#### Standard Treatment

Conventional or standard therapy for chronic wounds involves local wound care, as well as systemic measures including debridement of necrotic tissues, wound cleansing, and dressing that promotes a moist wound environment, antibiotics to control infection, and optimizing nutritional supplementation. Avoidance of weight-bearing is another important component of wound management.

#### **Electrostimulation**

Since the 1950s, investigators have used electrostimulation to promote wound healing, based on the theory that electrostimulation may:

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

- Increase adenosine 5'-triphosphate concentration in the skin
- Increase DNA synthesis
- Attract epithelial cells and fibroblasts to wound sites
- Accelerate the recovery of damaged neural tissue
- Reduce edema
- Increase blood flow
- Inhibit pathogenesis.

Electrostimulation refers to the application of electrical current through electrodes placed directly on the skin near the wound. The types of electrostimulation and devices can be categorized into groups based on the type of current. This includes low-intensity direct current, high-voltage pulsed current, alternating current, and transcutaneous electrical nerve stimulation.

#### **Electromagnetic Therapy**

Electromagnetic therapy is a related but distinct form of treatment that involves the application of electromagnetic fields, rather than direct electrical current.

## FDA or Other Governmental Regulatory Approval

### U.S. Food and Drug Administration (FDA)

No electrostimulation or electromagnetic therapy devices have received approval from the U.S. Food and Drug Administration specifically for the treatment of wound healing. A number of devices have been cleared for marketing for other indications. Use of these devices for wound healing is off-label.

## Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Electrostimulation (electrical stimulation) refers to the application of electrical current through electrodes placed directly on the skin. Electromagnetic therapy involves the application of

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

electromagnetic fields, rather than direct electrical current. Both are proposed as treatments for wounds, generally chronic wounds.

#### **Summary of Evidence**

For individuals who have any wound type (acute or nonhealing) who receive electrostimulation, the evidence includes systematic reviews and randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in health status, morbid events, quality of life, and treatment-related morbidity. Systematic reviews of RCTs on electrical stimulation have reported improvements in some outcomes, mainly intermediate outcomes such as a decrease in wound size and/or the speed of wound healing. There are few analyses of the more important clinical outcomes of complete healing and the time to complete healing, and many of the trials are relatively low quality. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have any wound type (acute or nonhealing) who receive electromagnetic therapy, the evidence includes 2 systematic reviews of RCTs (1 on pressure ulcers and the other on leg ulcers) and an RCT of electromagnetic treatment following Cesarean section. Relevant outcomes are symptoms, change in health status, morbid events, quality of life, and treatment-related morbidity. The systematic reviews identified a few RCTs with small sample sizes that do not permit drawing definitive conclusions. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

# **Supplemental Information**

#### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### **American College of Physicians**

In 2015, the American College of Physicians published guidelines on the treatment of pressure ulcers. The guidelines recommended that electrostimulation be used as adjunctive treatment in

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

individuals with pressure ulcers. This was considered by the College to be a weak recommendation, based on moderate-quality evidence. This guideline is listed as "inactive" on the ACP website.

#### Association for the Advancement of Wound Care

In 2014, the Association for the Advancement of Wound Care (AAWC) published guidelines on the care of venous ulcers and pressure ulcers. Guidelines for venous ulcer care included electrostimulation and electromagnetic stimulation as treatment modalities. Guidelines for pressure ulcer care include electrostimulation as adjunctive interventions when pressure ulcers do not respond to the first-line of treatment.

Previously, the AAWC (2010) published guidelines on the care of pressure ulcers. Electrostimulation was included as a potential second-line intervention if first-line treatments did not result in wound healing.

#### Wound, Ostomy and Continence Nurses Society

In 2016, the Wound, Ostomy and Continence Nurses Society published guidelines on the prevention and management of pressure ulcers. The guidelines stated that electrostimulation can be considered as adjunctive treatment and rated the evidence as level A.

#### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

#### **Medicare National Coverage**

National Medicare coverage of electrostimulation and electromagnetic stimulation is limited to chronic stage III or IV pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers.

Effective 2004, Medicare's national coverage decision is as follows:

- "ES and electromagnetic therapy will not be covered as an initial treatment modality.
- Continued treatment with ES and electromagnetic therapy is not covered if measurable signs of healing have not been demonstrated within any 30-day period of treatment.
- Unsupervised use of ES or electromagnetic therapy for wound therapy will not be covered....

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

All other uses of ES and electromagnetic therapy not otherwise specified for the treatment of wounds remain at local Medicare Administrative Contractor discretion."

#### **Ongoing and Unpublished Clinical Trials**

A search of <u>ClinicalTrials.gov</u> in November 2023 did not identify any ongoing or unpublished trials that would likely influence this review.

## References

- 1. Barnes R, Shahin Y, Gohil R, et al. Electrical stimulation vs. standard care for chronic ulcer healing: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Invest. Apr 2014; 44(4): 429-40. PMID 24456185
- 2. Franek A, Kostur R, Polak A, et al. Using high-voltage electrical stimulation in the treatment of recalcitrant pressure ulcers: results of a randomized, controlled clinical study. Ostomy Wound Manage. Mar 2012; 58(3): 30-44. PMID 22391955
- 3. Houghton PE, Campbell KE, Fraser CH, et al. Electrical stimulation therapy increases rate of healing of pressure ulcers in community-dwelling people with spinal cord injury. Arch Phys Med Rehabil. May 2010; 91(5): 669-78. PMID 20434602
- 4. Kawasaki L, Mushahwar VK, Ho C, et al. The mechanisms and evidence of efficacy of electrical stimulation for healing of pressure ulcer: a systematic review. Wound Repair Regen. 2014; 22(2): 161-73. PMID 24372691
- 5. Lala D, Spaulding SJ, Burke SM, et al. Electrical stimulation therapy for the treatment of pressure ulcers in individuals with spinal cord injury: a systematic review and meta-analysis. Int Wound J. Dec 2016; 13(6): 1214-1226. PMID 25869151
- 6. Liu LQ, Moody J, Traynor M, et al. A systematic review of electrical stimulation for pressure ulcer prevention and treatment in people with spinal cord injuries. J Spinal Cord Med. Nov 2014; 37(6): 703-18. PMID 24969965
- 7. Thakral G, La Fontaine J, Kim P, et al. Treatment options for venous leg ulcers: effectiveness of vascular surgery, bioengineered tissue, and electrical stimulation. Adv Skin Wound Care. Apr 2015; 28(4): 164-72. PMID 25775200
- 8. Zheng Y, Du X, Yin L, et al. Effect of electrical stimulation on patients with diabetes-related ulcers: a systematic review and meta-analysis. BMC Endocr Disord. Apr 27 2022; 22(1): 112. PMID 35477391

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

- 9. Arora M, Harvey LA, Glinsky JV, et al. Electrical stimulation for treating pressure ulcers. Cochrane Database Syst Rev. Jan 22 2020; 1(1): CD012196. PMID 31962369
- 10. Girgis B, Duarte JA. High Voltage Monophasic Pulsed Current (HVMPC) for stage II-IV pressure ulcer healing. A systematic review and meta-analysis. J Tissue Viability. Nov 2018; 27(4): 274-284. PMID 30177421
- 11. Khouri C, Kotzki S, Roustit M, et al. Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: An effect size meta-analysis. Wound Repair Regen. Sep 2017; 25(5): 883-891. PMID 29052946
- 12. Aziz Z, Flemming K. Electromagnetic therapy for treating pressure ulcers. Cochrane Database Syst Rev. Dec 12 2012; 12: CD002930. PMID 23235593
- 13. Aziz Z, Cullum N. Electromagnetic therapy for treating venous leg ulcers. Cochrane Database Syst Rev. Jul 02 2015; 2015(7): CD002933. PMID 26134172
- 14. Khooshideh M, Latifi Rostami SS, Sheikh M, et al. Pulsed Electromagnetic Fields for Postsurgical Pain Management in Women Undergoing Cesarean Section: A Randomized, Double-Blind, Placebo-controlled Trial. Clin J Pain. Feb 2017; 33(2): 142-147. PMID 28060214
- 15. Qaseem A, Humphrey LL, Forciea MA, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Mar 03 2015; 162(5): 370-9. PMID 25732279
- 16. American College of Physicians (ACP). Inactive ACP guidelines. https://www.acponline.org/clinical-information/guidelines/inactive-acp-guidelines.
- 17. Bolton LL, Girolami S, Corbett L, et al. The Association for the Advancement of Wound Care (AAWC) venous and pressure ulcer guidelines. Ostomy Wound Manage. Nov 2014; 60(11): 24-66. PMID 25380098
- 18. Association for the Advancement of Wound Care (AAWC). Association for the Advancement of Wound Care guideline of pressure ulcer guidelines. Malvern, PA: AAWC; 2010.
- 19. Wound, Ostomy and Continence Nurses Society-Wound Guidelines Task Force. WOCN 2016 Guideline for Prevention and Management of Pressure Injuries (Ulcers): An Executive Summary. J Wound Ostomy Continence Nurs. 2017; 44(3): 241-246. PMID 28472816
- 20. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of Wounds (270.1). 2004; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=131&ver=3.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

# **Policy History**

Original Effecti	ve Date: 04/29/2002
Current Effective	
04/18/2002	Medical Policy Committee review
04/29/2002	Managed Care Advisory Council approval
06/24/2002	Format revision. No substance change to policy.
08/03/2004	Medical Director review
08/17/2004	Medical Policy Committee review. Format revision. Policy change, eligible for
	coverage for identified uses.
08/30/2004	Managed Care Advisory Council approval
07/14/2005	Medical Director review
07/19/2005	Medical Policy Committee review. Coverage changed from "eligible" to
	investigational.
08/24/2005	Managed Care Advisory Council approval
07/07/2006	Format revision including addition of FDA and or other governmental regulatory
	approval and rationale/source. Coverage eligibility unchanged.
05/02/2007	Medical Director review
05/23/2007	Medical Policy Committee approval. Policy updated with literature review. Policy
	statement unchanged.
05/07/2009	Medical Director review
05/20/2009	Medical Policy Committee approval. Title changed from "Electrostimulation and
	Electromagnetic Stimulation as Treatment of Chronic Wounds" to
	"Electrostimulation and Electromagnetic Stimulation for the Treatment of Chronic
	Wounds". Policy updated with literature review. Policy statement unchanged.
06/03/2010	Medical Policy Committee review
06/16/2010	Medical Policy Implementation Committee approval.
05/05/2011	Medical Policy Committee review
05/18/2011	Medical Policy Implementation Committee approval. The word "Chronic" was
	deleted from the title.
05/03/2012	Medical Policy Committee review
05/16/2012	Medical Policy Implementation Committee approval. No change to coverage.
06/27/2013	Medical Policy Committee review and approval

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy #

00030

unchanged.

unchanged.

Medical Policy Committee review

Medical Policy Committee review

05/05/2022

05/11/2022

05/04/2023

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024 07/17/2013 Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged. 07/10/2014 Medical Policy Committee review and approval Medical Policy Implementation Committee review and approval. First 07/16/2014 investigational statement clarified. Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section 08/03/2015 removed. Medical Policy Committee review and approval 10/29/2015 Medical Policy Implementation Committee review and approval. Coverage 11/16/2015 eligibility unchanged. Medical Policy Committee review and approval 12/01/2016 Medical Policy Implementation Committee review and approval. Coverage 12/21/2016 eligibility unchanged. Coding update: Removing ICD-9 Diagnosis Codes 01/01/2017 Medical Policy Committee review and approval 12/07/2017 12/20/2017 Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged. Medical Policy Committee review and approval 12/06/2018 12/19/2018 Medical Policy Implementation Committee review and approval. Coverage eligibility unchanged. Coding update 01/01/2019 Medical Policy Committee review 12/05/2019 Medical Policy Implementation Committee approval. Coverage eligibility 12/11/2019 unchanged. Medical Policy Committee review 05/07/2020 Medical Policy Implementation Committee approval. Coverage eligibility 05/13/2020 unchanged. Medical Policy Committee review 05/06/2021 Medical Policy Implementation Committee approval. Coverage eligibility 05/12/2021

©2024 Blue Cross and Blue Shield of Louisiana

Medical Policy Implementation Committee approval. Coverage eligibility

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

05/10/2023 Medical Policy Implementation Committee approval. Coverage eligibility

unchanged.

05/02/2024 Medical Policy Committee review

05/08/2024 Medical Policy Implementation Committee approval. Coverage eligibility

unchanged.

Next Scheduled Review Date: 05/2025

# **Coding**

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	No codes
HCPCS	E0761, E0769, G0281, G0282, G0295, G0329 Delete codes effective 06/01/2024: C1816, C1883
ICD-10 Diagnosis	All related diagnoses

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
  - 1. Consultation with technology evaluation center(s);
  - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
  - 3. Reference to federal regulations.

\*\*Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00030

Original Effective Date: 04/29/2002 Current Effective Date: 06/10/2024

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

**NOTICE:** Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.